Evaluation of anticancer properties and molecular mechanisms of action of new hybrid molecules containing uracil skeleton with an exo-cyclic methylene group
2017/25/N/NZ3/01039
Keywords
Descriptors
- NZ1_1: Biologia molekularna
- NZ3_1: Biologia komórki
- NZ7_14: Farmacja, farmakoterapia, farmakologia
Panel
NZ3 – Cellular and developmental biology: cell biology, developmental biology, ageing biology, neurobiology
Host institution
Uniwersytet Medyczny w Łodzi, Wydział Lekarski
Voivodeship: łódzkie
Principal investigator (from the host institution)
dr Angelika Agata Długosz-Pokorska
Number of co-investigators in the project: 2
Call
PRELUDIUM 13 – announced on 2017-03-15
- Amount awarded
- 149 700 PLN
- Project start date
- 2018-03-22
- Project end date
- 2024-09-21
- Project duration
- 78 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (5)
-
New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells.
- Authors:
- Angelika Długosz-Pokorska , Renata Perlikowska , Tomasz Janecki , Anna Janecka
- Academic press:
- Biologics: Targets and Therapy (year: 2023, volume: 17, pages: 69–83), Publisher: Dovepress
- Status:
- Published
- DOI:
- 10.2147/BTT.S405080 – link to the publication
-
New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line.
- Authors:
- Długosz-Pokorska Angelika, Pięta Marlena, Janecki Tomasz, Janecka Anna
- Academic press:
- Molecular Biology Reports (year: 2019, volume: 46(6), pages: 5831-5839), Publisher: Springer Science+Business Media
- Status:
- Published
- DOI:
- 10.1007/s11033-019-05017-w – link to the publication
-
New uracil analog with exocyclic methylidene group as potential anticancer agent.
- Authors:
- Angelika Długosz-Pokorska, Joanna Drogosz, Marlena Pięta, Tomasz Janecki, Urszula Krajewska, Marek Mirowski, Anna Janecka
- Academic press:
- Anti-Cancer Agents in Medicinal Chemistry (year: 2020, volume: 20, pages: 359-368), Publisher: Bentham Science Publishers
- Status:
- Published
- DOI:
- 10.2174/1871520619666191211104128 – link to the publication
-
New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line
- Authors:
- Angelika Długosz-Pokorska, Marlena Pięta, Jacek Kędzia, Tomasz Janecki, Anna Janecka
- Academic press:
- BMC Pharmacology and Toxicology (year: 2020, volume: 21, pages: 46032), Publisher: Springer
- Status:
- Published
- DOI:
- 10.1186/s40360-020-0397-4 – link to the publication
-
New uracil analog as inhibitor/modulator of ABC transporters or/and NF‑κB in taxol‑resistant MCF‑7/Tx cell line
- Authors:
- Angelika Długosz‑Pokorska · Tomasz Janecki · Anna Janecka · Katarzyna Gach‑Janczak
- Academic press:
- Journal of Cancer Research and Clinical Oncology (year: 2024, volume: 150, pages: 46033), Publisher: Springer
- Status:
- Published
- DOI:
- 10.1007/s00432-024-05833-z – link to the publication
Articles in post-conference publications (1)
-
New Uracil Analog- U-359 can reverse resistance to Taxol in MCF-7 cancer cells
- Authors:
- Angelika Długosz-Pokorska, Renata Perlikowska, Tomasz Janecki, Anna Janecka
- Conference:
- the 5th BIO Congress (year: 2023, pages: 56), Publisher: Acta Biochmica Polonica
- Date:
- conference 13-16.09.2023
- Status:
- Published